Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
But does it hit hard enough?
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
A miss for Roche’s Akt inhibitor in advanced breast cancer leaves questions over population and combination.
Licensing deal could enable bundling of antipsychotics with management technology.